Weiketuo Velinotamig Injection

1. Indications and Usage
Relapsed or Refractory Multiple Myeloma: For adult patients with relapsed or refractory multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
2. Dosage and Administration
Approved Status: Conditionally approved in China; official English dosing schedule has not been published.
Route: Intravenous infusion under the supervision of qualified healthcare professionals.
Dose Selection: Dose, schedule, premedication, and infusion-rate guidance should follow the approved Chinese label and institutional protocols.
3. Mechanism of Action
BCMA × CD3 Bispecific Antibody: Velitelimab is a bispecific antibody that simultaneously binds BCMA on multiple myeloma cells and CD3 on T cells.
T-Cell–Mediated Cytotoxicity: By bridging T cells and BCMA-expressing tumor cells, it redirects T-cell cytotoxicity to induce tumor cell killing.
4. Safety and Warnings
Cytokine Release Syndrome: CRS is an expected class risk for BCMA×CD3 bispecific antibodies and requires early recognition and management.
Infections and Cytopenias: Risk of serious infections, neutropenia, and other hematologic toxicities should be monitored.
Neurologic Toxicity: Neurologic adverse events, including immune effector cell–associated neurotoxicity syndrome, may occur.
Infusion/Hypersensitivity Reactions: Monitor for infusion-related reactions and hypersensitivity.
Conditional Approval: Efficacy and safety are still being confirmed through post-approval studies.
5. Adverse Reactions and Clinical Research
Adverse Reactions: Expected class-related events include CRS, infections, cytopenias, infusion reactions, and neurologic events; exact frequencies should be obtained from the approved Chinese label.
Clinical Research: The drug was included in China’s Breakthrough Therapy designation program in 2024 and received conditional approval in 2026 based on clinical data in relapsed or refractory multiple myeloma.
6. Drug Interactions
No English Interaction Data Available: Formal English drug-interaction information has not been published.
Clinical Caution: Concomitant immunosuppressants, live vaccines, or other therapies affecting immune function should be managed according to the approved label and treating physician guidance.
7. Pharmaceutical Information
International Nonproprietary Name: Velitelimab.
Chinese Brand Name: 维可妥.
Development Code: GR1803.
Drug Class: BCMA × CD3 bispecific antibody.
Dosage Form: Injection for intravenous infusion.
Approval: Conditionally approved by China NMPA in 2026.
Storage and Handling: Refer to the approved Chinese package insert for strength, excipients, storage conditions, and shelf life.